News Archive

2022

April

Media Release / Apr 12, 2022

Novartis presents new four-year data on efficacy and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis

Read More
Media Release / Apr 06, 2022

FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Read More

March

Media Release / Mar 23, 2022

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer

Read More
2021

December

Media Release / Dec 22, 2021

Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis

Read More
Media Release / Dec 22, 2021

FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year

Read More
Media Release / Dec 13, 2021

Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021

Read More
Media Release / Dec 11, 2021

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

Read More
Media Release / Dec 10, 2021

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

Read More
Media Release / Dec 08, 2021

New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Read More

November

Media Release / Nov 08, 2021

Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021

Read More

Related Links